HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a painkiller blocker boost cancer immunotherapy?
Disease control Not yet recruitingThis early-phase trial tests whether adding axelopran—a drug that blocks opioid effects on the immune system—can help pembrolizumab (an immunotherapy) work better in people with advanced head and neck cancer who take opioids for pain. About 18 participants will receive both drugs…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M)
Phase: PHASE1, PHASE2 • Sponsor: Glycyx Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New scan could sharpen detection of head and neck cancers
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 64Cu-DOTA-ECL1i that aims to make PET scans more accurate for head and neck cancer. Researchers will enroll 90 adults with newly diagnosed or recurrent/metastatic head and neck squamous cell carcinoma. The goal is to see if this tr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M)
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC